Market Research Logo

The Global Influenza Market

The Global Influenza Market

The global influenza market reached $5.1 billion in 2015. This market is expected to increase from $5.4 billion in 2016 to $6.4 billion in 2021 at a compound annual growth rate (CAGR) of 3.6% for 2016-2021. 

Report Includes
An overview of the global market for influenza vaccines, therapeutics, and diagnostics.
Analyses of global market trends, with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021.
Information about products available, products in development, issues and trends influencing the market, and competitive analysis of top providers, with a special emphasis on U.S. and European markets.
Discussion of efforts by government agencies and disease prevention organizations to support and fund research and development programs, and pandemic prevention.
Analysis of the market's dynamics, specifically growth drivers, restraints, and opportunities.
Profiles of major players in the industry.


Report Scope
This BCC Research report is designed to be a helpful business tool that provides a thorough evaluation of the market for influenza vaccines, therapeutics and diagnostics. The geographic scope of this study is worldwide, with emphasis on U.S. and European data. The report identifies markets in general segments: Vaccines/Therapeutics and Diagnostics. Each market segment discussion provides detailed information based on product categories, uses of products, forecasts and competitive analyses. Additionally, the study covers some of the most significant issues, trends and market factors.

CHAPTER 1 INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE OF REPORT
METHODOLOGY AND INFORMATION SOURCES
RELATED BCC RESEARCH REPORTS
ANALYST'S CREDENTIALS
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 SUMMARY
THE INFLUENZA MARKET: MAJOR MARKETS SUMMARY
SUMMARY TABLE GLOBAL INFLUENZA MARKET, BY PRODUCT SEGMENT, THROUGH 2021 ($ MILLIONS)
SUMMARY FIGURE GLOBAL INFLUENZA MARKET, BY PRODUCT SEGMENT, 2010-2021 ($ MILLIONS)
CHAPTER 3 INDUSTRY OVERVIEW
OVERVIEW
HISTORY OF THE MARKET
EPIDEMICS/PANDEMICS
Spanish Influenza 1918–1919
Hong Kong Influenza 1968
Asian Influenza 1957
Swine Flu 1976
Russian Influenza 1977
Avian Flu 1961, 1997, 2003-2009/2010 (sporadic)
Novel Influenza H1N1 2009
TABLE 1 DISTRIBUTION OF FATAL CASES OF H1N1 PANDEMIC BY WHO REGIONS, 2009-2010
CDC Reported 2009 H1N1 Cases in the U.S.
TABLE 2 CDC ESTIMATES OF 2009 H1N1 CASES AND RELATED
HOSPITALIZATIONS AND DEATHS, BY AGE GROUP, APRIL 2009 - MARCH 13, 2010
Influenza H7N9 2013
TABLE 3 CUMULATIVE NUMBER OF CONFIRMED CASES OF H7N9, BY REGION, OCTOBER 2016
VIRUS MUTATIONS
TYPES OF INFLUENZA
Influenza Type A
Influenza Type B
Influenza Type C
WORLD ACTIVITY OF INFLUENZA VIRUSES
FIGURE 1 WORLDWIDE INFLUENZA ACTIVITY OCTOBER 2014 - MAY 2015
FIGURE 2 WORLDWIDE INFLUENZA ACTIVITY MAY 2015 - SEPTEMBER 2015
THE WORLD HEALTH ORGANIZATION (WHO) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC): INFLUENZA RESPONSE
WORLD HEALTH ORGANIZATION
CENTERS FOR DISEASE CONTROL AND PREVENTION
U.S. VIRAL SURVEILLANCE
TABLE 4 VIRAL SURVEILLANCE BY FLU SEASONS AND PERCENTAGE OF INFLUENZA VIRUS TYPE, 2005-2017 (%)
FIGURE 3 VIRAL SURVEILLANCE BY FLU SEASONS AND PERCENTAGE OF INFLUENZA VIRUS TYPE, 2005-2017 (%)
FDA'S VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY
COMMITTEE AND VACCINE COMPOSITION
TABLE 5 INFLUENZA VIRUS RECOMMENDATIONS FOR U.S. INFLUENZA
SEASONS, 2003-2017
VACCINE RECOMMENDATIONS
TABLE 6 THIMEROSAL CONTENT OF INFLUENZA VACCINES (U.S. MANUFACTURED)
TABLE 7 CDC INFLUENZA VACCINE RECOMMENDATIONS FOR ALL PEOPLE
FROM 6 MONTHS OF AGE
FIGURE 4 RECOMMENDATIONS REGARDING INFLUENZA VACCINATION OF PERSONS ALLERGIC TO EGGS: ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES FOR U.S. INFLUENZA SEASON, 2015-2016
VACCINE EFFECTIVENESS
TABLE 8 ADJUSTED VACCINE EFFECTIVENESS ESTIMATES FOR INFLUENZA SEASONS, 2005-2016
UNIVERSAL VACCINE
INFLUENZA PREPAREDNESS AND RAPID PRODUCTION
POPULATION DEMOGRAPHICS AND INFLUENZA INCIDENCE/MORTALITY
GLOBAL DEMOGRAPHICS
TABLE 9 GLOBAL POPULATION BY SELECTED AGE GROUP, 2010-2050 (MILLIONS)
FIGURE 5 GLOBAL POPULATION BY SELECTED AGE GROUP, 2010-2050 (MILLIONS)
TABLE 10 GLOBAL POPULATION AVERAGE GROWTH BY BROAD AGE GROUP, 2010-2050 (%)
FIGURE 6 GLOBAL POPULATION AVERAGE GROWTH BY BROAD AGE GROUP, 2010-2050 (%)
TABLE 11 GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2020
FIGURE 7 GLOBAL POPULATION BY SELECTED COUNTRY, 2010- 2020
(MILLIONS)
GLOBAL LIFE EXPECTANCY
TABLE 12 GLOBAL LIFE EXPECTANCY AT BIRTH, BY SELECTED COUNTRY, 1980-2020 (YEARS)
FIGURE 8 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980-2020 (YEARS)
INFLUENZA INCIDENCE AND MORTALITY
TABLE 13 IMPACT OF 2009 H1N1 FLU, CASES AND RELATED
HOSPITALIZATIONS AND DEATHS BY AGE GROUP, APRIL
2009-2010
CHAPTER 4 ISSUES AFFECTING THE MARKET
H1N1 OUTBREAK 2009 (SWINE FLU)
RAPID DIAGNOSTICS
Pandemic Testing
Seasonal Influenza Tests
AVIAN FLU
TABLE 14 COUNTRIES/REGIONS AFFECTED BY CURRENT CDC AND USDA
BIRD IMPORT RESTRICTIONS
AVIAN FLU SURVEILLANCE
TABLE 15 WHO-REPORTED CASES OF AVIAN INFLUENZA A/ (H5N1) IN HUMANS
FIGURE 9 WHO-REPORTED CASES OF AVIAN INFLUENZA A/(H5N1) IN HUMANS, 2003-2016* (NO.)
The WHO and Containment for Pandemic Influenza
FIGURE 10 APPROVED WHO INFLUENZA CENTERS BY WHO BROAD REGION (%)
INTERNATIONAL INFLUENZA VACCINE STOCKPILE ORDERS
PRE-PANDEMIC VACCINATION
FIGURE 11 TARGETED PRE-PANDEMIC INFLUENZA VACCINE STOCKPILES, BASED ON POPULATION DEMANDS FOR SELECTED COUNTRIES (MILLION)
Biomedical Advanced Research and Development Authority (BARDA)
ANTIVIRAL RESISTANCE
RECREATED VIRUSES
IMMATERIALIZED MARKET RISK
MEDIA COVERAGE AND VACCINATIONS
EPIDEMIC/PANDEMIC THREAT
TABLE 16 ESTIMATED INCIDENCE OF PANDEMIC INFLUENZA, SEVERE OUTBREAKS BASED ON 2017-PROJECTED POPULATION (U.S. CENSUS BUREAU INTERNATIONAL DATABASE SELECTED COUNTRIES)
(THOUSANDS)
PANDEMIC PREPAREDNESS PLANS
TABLE 17 ESSENTIAL AND DESIRABLE ELEMENTS OF THE WHO INFLUENZA
PANDEMIC PREPAREDNESS PLAN
INFRARED SENSORS AND THERMAL IMAGERS
THE UNITED STATES
JAPAN
TABLE 18 OUTLINE OF JAPAN'S GOVERNMENT ACTION PLAN FOR INFLUENZA PANDEMIC PREPAREDNESS
CHINA
TABLE 19 CHINA'S INFLUENZA PANDEMIC WARNING LEVELS
BRAZIL
TABLE 20 BRAZIL'S INFLUENZA PANDEMIC WARNING LEVELS AND ACTION
UNITED KINGDOM
WORLD INFLUENZA IMPACT
CHAPTER 5 PATENT ANALYSIS
OVERVIEW
INFLUENZA PATENTS BY PATENT NUMBER
TABLE 21 PATENTS FOR INFLUENZA, BY YEAR ISSUED, 2002-2016
FIGURE 12 PATENTS FOR INFLUENZA BY YEAR ISSUED, 2002-2016
TABLE 22 RECENT U.S. PATENTS FOR INFLUENZA TECHNOLOGY, BY PATENT NUMBER
TABLE 23 NUMBER OF U.S. PATENTS BY INFLUENZA MARKET COMPETITOR
EMORY UNIVERSITY
GLAXOSMITHKLINE BIOLOGICALS SA
LONGHORN VACCINES AND DIAGNOSTICS LLC
NOVARTIS
NOVAVAX
SHIONOGI & CO. LTD.
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
UNIVERSITY OF PENNSYLVANIA
VERTEX PHARMACEUTICALS INC.
WISCONSIN ALUMNI RESEARCH FOUNDATION
CHAPTER 6 INFLUENZA VACCINES
OVERVIEW
HISTORY OF VACCINE MANUFACTURER PARTICIPATION IN THE U.S.
TABLE 24 INFLUENZA VACCINE MANUFACTURER PARTICIPATION IN THE U.S., 2004-2017
CURRENT VACCINES
ASTRAZENECA - MEDIMMUNE
SEQIRUS - CSL
GLAXOSMITHKLINE
MYLAN
NANOTHERAPEUTICS
PROTEIN SCIENCES CORP.
SANOFI PASTEUR
SINOVAC BIOTECH
TABLE 25 EXAMPLES OF MARKETED SEASONAL INFLUENZA VACCINE
PRODUCTS
SEASONAL 2016-2017 VACCINE APPROVALS BY FDA
TABLE 26 SEASONAL INFLUENZA VACCINE FDA APPROVALS BASED ON ADULT DOSAGE, 2016-2017
PANDEMIC INFLUENZA VACCINES
TABLE 27 EXAMPLES OF APPROVED PANDEMIC INFLUENZA VACCINE PRODUCTS
VACCINE DEVELOPMENTS
CLINICAL TRIALS
TABLE 28 CLINICAL TRIALS FOR INFLUENZA PREVENTION (VACCINES AND BIOLOGICS) BY SELECTED COUNTRY AND TRIAL STATUS
BIKEN
TABLE 29 BIKEN INFLUENZA VACCINE PIPELINE
BiondVax Pharmaceuticals
TABLE 30 BIONDVAX PHARMACEUTICALS INFLUENZA VACCINE
PIPELINE
Changchun BCHT Biotechnology Co.
TABLE 31 CHANGCHUN BCHT BIOTECHNOLOGY INFLUENZA VACCINE
PIPELINE
Eurocine Vaccines AB
TABLE 32 EUROCINE VACCINES INFLUENZA VACCINE PIPELINE
Institute of Vaccines and Medical Biologicals, Vietnam
TABLE 33 INSTITUTE OF VACCINES AND MEDICAL BIOLOGICALS, VIETNAM INFLUENZA VACCINE PIPELINE
Longeveron LLC
TABLE 34 LONGEVERON LLC INFLUENZA VACCINE PIPELINE
MedImmune
TABLE 35 MEDIMMUNE INFLUENZA VACCINE PIPELINE
Mitsubishi Tanabe
TABLE 36 MITSUBISHI TANABE'S INFLUENZA VACCINE PIPELINE
NanoBio Corp.
TABLE 37 NANOBIO CORP. INFLUENZA VACCINE PIPELINE
Nanotherapeutics Inc.
TABLE 38 NANOTHERAPEUTICS' INFLUENZA VACCINE PIPELINE
NanoViricides Inc.
TABLE 39 NANOVIRICIDES INFLUENZA VACCINE PIPELINE
NexBio Inc.
TABLE 40 NEXBIO CORPORATION INFLUENZA VACCINE PIPELINE
Nitto Denko Corporation
TABLE 41 NITTO DENKO CORPORATION INFLUENZA VACCINE PIPELINE
Novavax, Inc.
TABLE 42 NOVAVAX INFLUENZA VACCINE PIPELINE
Pantec Biosolutions AG
PaxVax Corp.
TABLE 43 PAXVAX CORPORATION INFLUENZA VACCINE PIPELINE
PepTcell Limited
TABLE 44 PEPTCELL LTD. INFLUENZA VACCINE PIPELINE
Protein Sciences Corp.
TABLE 45 PROTEIN SCIENCES INFLUENZA VACCINE PIPELINE
Sanofi Pasteur
TABLE 46 SANOFI PASTEUR INFLUENZA VACCINE PIPELINE
Seqirus
TABLE 47 SEQIRUS INFLUENZA VACCINE PIPELINE
Vaxart Inc.
TABLE 48 VAXART INFLUENZA VACCINE PIPELINE
THE GLOBAL INFLUENZA VACCINE MARKET
TABLE 49 GLOBAL MARKET FOR INFLUENZA VACCINES, BY MANUFACTURER, THROUGH 2021 ($ MILLIONS)
FIGURE 13 GLOBAL MARKET FOR INFLUENZA VACCINES, BY MANUFACTURER, 2010-2021 ($ MILLIONS)
Seasonal vs. Pandemic Sales
FIGURE 14 GLOBAL MARKET FOR INFLUENZA VACCINES BY SEASONAL VS. PANDEMIC SUPPLY ORDERS, 2007-2016 ($ MILLIONS)
REGIONAL MARKET SUMMARY
TABLE 50 GLOBAL MARKET FOR INFLUENZA VACCINES, BY REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 15 GLOBAL MARKET FOR INFLUENZA VACCINES, BY REGION, 2010-2021 ($ MILLIONS)
FIGURE 16 DISTRIBUTION OF GLOBAL INFLUENZA VACCINE SALES, BY REGION, 2016 (%)
The U.S. Influenza Vaccine Market
TABLE 51 U.S. MARKET FOR INFLUENZA VACCINES BY MANUFACTURER, THROUGH 2021 ($ MILLIONS)
FIGURE 17 U.S. MARKET FOR INFLUENZA VACCINES BY MANUFACTURER, 2010-2021 ($ MILLIONS)
TABLE 52 ESTIMATED TOTAL UNITS SHIPPED TO THE U.S., BY SEASON, 2005-2017
FIGURE 18 ESTIMATED TOTAL UNITS SHIPPED TO THE U.S. BY SEASON, 2005-2017 (MILLIONS)
TABLE 53 UNITS FOR INFLUENZA VACCINES DISTRIBUTED IN THE U.S., BY MANUFACTURER, 2016-2017 (UNITS PER MILLION/%)
The European Influenza Vaccine Market
TABLE 54 ESTIMATED INFLUENZA VACCINE SALES DISTRIBUTION IN EU, BY COUNTRY, 2016-2017 (%)
TABLE 55 EUROPE'S MARKET FOR INFLUENZA VACCINES, BY MANUFACTURER, THROUGH 2021 ($ MILLIONS)
FIGURE 19 EUROPE'S MARKET FOR INFLUENZA VACCINES, BY MANUFACTURER, 2010-2021 ($ MILLIONS)
GLOBAL COMPETITOR ANALYSIS
TABLE 56 GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2013-2016 (%)
FIGURE 20 GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2013 (%)
FIGURE 21 GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2014 (%)
FIGURE 22 GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2015 (%)
FIGURE 23 GLOBAL MARKET SHARE FOR INFLUENZA VACCINES, BY LEADING PARTICIPANT, 2016 (%)
CHAPTER 7 INFLUENZA THERAPIES
OVERVIEW
CURRENT THERAPIES
DAIICHI SANKYO
GLAXOSMITHKLINE
ROCHE
BIOCRYST PHARMACEUTICALS/SEQIRUS
OTHERS
TABLE 57 MARKETED THERAPIES, BY COMPANY, 2016
GENERIC AVAILABILITY
TABLE 58 GENERIC FDA APPROVALS OF INFLUENZA APPROVED
TREATMENTS
INFLUENZA TREATMENT DEVELOPMENTS
CLINICAL TRIALS
TABLE 59 CLINICAL TRIALS FOR INFLUENZA THERAPEUTICS, BY SELECTED COUNTRY AND TRIAL STATUS
Amarillo Biosciences Inc.
TABLE 60 AMARILLO BIOSCIENCES INFLUENZA TREATMENT PIPELINE
AstraZeneca (MedImmune)
TABLE 61 ASTRAZENECA INFLUENZA TREATMENT PIPELINE
Genentech
TABLE 62 GENENTECH INFLUENZA TREATMENT PIPELINE
GlaxoSmithKline
TABLE 63 GLAXOSMITHKLINE INFLUENZA TREATMENT PIPELINE
Hemispherx Biopharma
TABLE 64 HEMISPHERX BIOPHARMA INFLUENZA TREATMENT
PIPELINE
Il-Yang Pharm
TABLE 65 IL-YANG INFLUENZA TREATMENT PIPELINE
Janssen Pharmaceutical Company
TABLE 66 JANSSEN PHARMACEUTICAL CO. INFLUENZA TREATMENT
PIPELINE
Materia Medica Holding
TABLE 67 MATERIA MEDICA INFLUENZA TREATMENT PIPELINE
Romark Laboratories
TABLE 68 ROMARK LABORATORIES INFLUENZA TREATMENT PIPELINE
Sarepta Therapeutics
TABLE 69 SAREPTA THERAPEUTICS INFLUENZA TREATMENT PIPELINE
Shionogi
TABLE 70 SHIONOGI INFLUENZA TREATMENT PIPELINE
Toyama Chemical
TABLE 71 TOYAMA CHEMICAL INFLUENZA TREATMENT PIPELINE
Visterra Inc.
TABLE 72 VISTERRA INFLUENZA TREATMENT PIPELINE
THE GLOBAL INFLUENZA THERAPEUTICS MARKET
TABLE 73 GLOBAL MARKET FOR INFLUENZA THERAPEUTICS, BY MANUFACTURER, THROUGH 2021 ($ MILLIONS)
FIGURE 24 GLOBAL MARKET FOR INFLUENZA THERAPEUTICS, BY MANUFACTURER, 2010-2021 ($ MILLIONS)
REGIONAL MARKET SUMMARY
TABLE 74 GLOBAL MARKET FOR INFLUENZA THERAPEUTICS, BY REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 25 GLOBAL MARKET FOR INFLUENZA THERAPEUTICS, BY REGION, 2010-2021 ($ MILLIONS)
FIGURE 26 DISTRIBUTION OF GLOBAL INFLUENZA THERAPEUTICS SALES, BY REGION, 2016 (%)
COMPETITOR ANALYSIS
TABLE 75 GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2013-2016 (%)
FIGURE 27 GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2013 (%)
FIGURE 28 GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2014 (%)
FIGURE 29 GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2015 (%)
FIGURE 30 GLOBAL MARKET SHARE FOR INFLUENZA THERAPEUTICS, BY LEADING PARTICIPANT, 2016 (%)
CHAPTER 8 INFLUENZA DIAGNOSTICS
OVERVIEW
TABLE 76 INFLUENZA DIAGNOSTIC TABLE
TEST DESCRIPTIONS[2]
Viral Culture
Rapid Influenza Diagnostic Tests
TABLE 77 CLINICAL CONSIDERATIONS OF RAPID TESTING DURING
HIGH INFLUENZA PREVALENCE
TABLE 78 CLINICAL CONSIDERATIONS OF RAPID TESTING DURING
LOW INFLUENZA PREVALENCE
Serologic Testing
PRODUCT DESCRIPTION
Alere
Becton Dickinson
BTNX Inc.
Cepheid
Hologic Inc.
Luminex Corp.
Meridian Biosciences Inc.
OraSure Technologies
Qiagen
Quidel Corp.
Remel Inc. (Thermo Scientific)
Response Biomedical Corp.
SA Scientific Ltd.
Sekisui Diagnostics
Thermo Fisher Scientific
TABLE 79 SELECTED MARKETED RAPID TEST PRODUCTS, DECEMBER
2016
TABLE 80 AVERAGE PRICE OF SELECTED RAPID INFLUENZA TESTS ($)
LABORATORY SERVICES
Associated Regional University Pathologists (ARUP) Laboratories
Bio-Reference Laboratories Inc.
Laboratory Corp. of America
Pathology Associates Medical Laboratories
Quest Diagnostics
TABLE 81 PROVIDERS OF TEST SERVICES
MARKET ANALYSIS
TABLE 82 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY PRODUCT CLASSIFICATION, THROUGH 2021 ($ MILLIONS)
FIGURE 31 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY PRODUCT CLASSIFICATION, 2010-2021 ($ MILLIONS)
FIGURE 32 DISTRIBUTION OF GLOBAL INFLUENZA DIAGNOSTICS SALES, BY PRODUCT CLASSIFICATION, 2016 (%)
FIGURE 33 DISTRIBUTION OF CONVENTIONAL LABORATORY INFLUENZA DIAGNOSTICS SALES, BY PRODUCT TYPE, 2016 (%)
FIGURE 34 DISTRIBUTION OF RAPID INFLUENZA DIAGNOSTICS SALES, BY PRODUCT TYPE, 2016 (%)
REGIONAL MARKET SUMMARY
TABLE 83 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 35 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY REGION, 2010-2021 ($ MILLIONS)
FIGURE 36 DISTRIBUTION OF GLOBAL INFLUENZA DIAGNOSTICS SALES, BY REGION, 2016 (%)
TABLE 84 NUMBER OF CLIA-WAIVED TESTS APPROVED, BY YEAR FOR INFLUENZA INDICATIONS IN THE U.S., 2000-2016*
FIGURE 37 NUMBER OF CLIA-WAIVED TESTS APPROVED, BY YEAR FOR INFLUENZA INDICATIONS IN THE U.S., 2000-2016*
COMPETITOR ANALYSIS
TABLE 85 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANT, 2013-2016 (%)
FIGURE 38 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANT, 2013 (%)
FIGURE 39 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANTS, 2014 (%)
FIGURE 40 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANTS, 2015 (%)
FIGURE 41 GLOBAL MARKET FOR INFLUENZA DIAGNOSTICS, BY LEADING PARTICIPANTS, 2016 (%)
CHAPTER 9 INFLUENZA MARKET SUMMARY
OVERVIEW OF INFLUENZA MARKET TRENDS
TABLE 86 INFLUENZA VACCINE MARKET DRIVERS AND RESISTORS
TABLE 87 INFLUENZA THERAPEUTIC MARKET DRIVERS AND RESISTORS
TABLE 88 INFLUENZA DIAGNOSTIC MARKET DRIVERS AND RESISTORS
TOTAL MARKET ANALYSIS
TABLE 89 GLOBAL INFLUENZA MARKET, BY PRODUCT SEGMENT, THROUGH 2021 ($ MILLIONS)
FIGURE 42 GLOBAL INFLUENZA MARKET, BY PRODUCT SEGMENT, 2010-2021 ($ MILLIONS)
FIGURE 43 DISTRIBUTION OF GLOBAL INFLUENZA MARKET, BY REVENUE SEGMENT, 2016 (%)
REGIONAL MARKET SUMMARY
TABLE 90 GLOBAL INFLUENZA MARKET, BY REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 44 GLOBAL INFLUENZA MARKET, BY REGION, 2010-2021 ($ MILLIONS)
FIGURE 45 DISTRIBUTION OF GLOBAL INFLUENZA MARKET, BY REGION, 2016 (%)
CHAPTER 10 COMPANY PROFILES
SIGNIFICANT COMPANY ACQUISITIONS
ALERE INC.
TABLE 91 ALERE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
FIGURE 46 ALERE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
ASTRAZENECA/MEDIMMUNE
TABLE 92 ASTRAZENECA'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
FIGURE 47 ASTRAZENECA'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
BECTON DICKINSON AND COMPANY
TABLE 93 BECTON DICKINSON'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
FIGURE 48 BECTON DICKINSON'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
CEPHEID
TABLE 94 DANAHER'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
FIGURE 49 DANAHER'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
DAIICHI SANKYO
TABLE 95 DAIICHI SANKYO'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
FIGURE 50 DAIICHI SANKYO'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
GLAXOSMITHKLINE PLC
TABLE 96 GLAXOSMITHKLINE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
FIGURE 51 GLAXOSMITHKLINE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
HOLOGIC INC.
TABLE 97 HOLOGIC'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
FIGURE 52 HOLOGIC'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
MITSUBISHI TANABE PHARMA CORP.
TABLE 98 MITSUBISHI TANABE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
FIGURE 53 MITSUBISHI TANABE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
MYLAN N.V.
TABLE 99 MYLAN'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
FIGURE 54 MYLAN'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
ORASURE TECHNOLOGIES
TABLE 100 ORASURE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
FIGURE 55 ORASURE'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
PROTEIN SCIENCES CORPORATION
QIAGEN N.V.
TABLE 101 QIAGEN'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
FIGURE 56 QIAGEN'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
QUIDEL CORP.
TABLE 102 QUIDEL'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
FIGURE 57 QUIDEL'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
ROCHE LTD.
TABLE 103 ROCHE GROUP'S REVENUES, 2013-2016 ($ MILLIONS)
FIGURE 58 ROCHE GROUP'S REVENUES, 2013-2016 ($ MILLIONS)
SANOFI/SANOFI PASTEUR
TABLE 104 SANOFI'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
FIGURE 59 SANOFI'S COMPANY REVENUES, 2013-2016 ($ MILLIONS)
SEKISUI DIAGNOSTICS LLC
TABLE 105 SEKISUI CHEMICAL CO.'S REVENUES, 2013-2016* ($ BILLIONS)
FIGURE 60 SEKISUI CHEMICAL CO.'S REVENUES, 2013-2016* ($ BILLIONS)
SEQIRUS CSL LIMITED
TABLE 106 CSL LIMITED'S COMPANY REVENUES, 2013-2016* ($ MILLIONS)
FIGURE 61 CSL LIMITED'S COMPANY REVENUES, 2013-2016* ($ MILLIONS)
CHAPTER 11 APPENDICES
APPENDIX I
MANUFACTURERS AND DEVELOPERS
APPENDIX II
TABLE 107 APPROVED WHO INFLUENZA CENTERS BY REGION
APPENDIX III
GLOSSARY OF TERMS[3]
LIST OF ACRONYMS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report